News and reporting on cell-free DNA testing.
Micronoma, NYU Partner to Develop Microbial Biomarkers of Lung Cancer
Micronoma aims to commercialize the biomarkers as a test based on its OncobiotaLUNG microbiome-based liquid biopsy platform.
Guardant Health Secures New Commercial Payor Coverage for Liquid Biopsy Cancer Profiling Test
With new coverage from Anthem Blue Cross and Blue Shield, Aetna, and Humana, the firm's Guardant360/Guardant360 CDx assay is now covered by all major commercial health insurers.
Personalis, Ono Pharmaceutical, Japan National Cancer Center Partner on Opdivo Rectal Cancer Trial
In the multicenter VOLTAGE-2 trial, investigators will compare results of the company's tests with standard-of-care measures of drug response.
Aspira Women's Health Licenses Dana-Farber microRNA Signature; Firm Executes Reverse Stock Split
Aspira Women's Health has been evaluating Dana-Farber's microRNA technology for ovarian cancer detection since early 2021.
Guardant Health Pushing Hard to Contextualize CRC Screening Data as Core Business Chugs Along
The company is seeing continuing growth for its existing clinical products as it moves resources toward commercialization of its Guardant Shield CRC screening test.